Navigation Links
LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Date:9/1/2009

ses," said Roger E. Morgan, M.D., Chief Medical Officer, Kowa Research Institute. "With sustained efficacy, low rates of discontinuation due to adverse events and steady, progressive increases in HDL-C observed over 52 weeks, LIVALO shows great promise for the long-term treatment of patients with hypercholesterolemia or mixed dyslipidemia."

Study 1

A total of 830 patients were randomized to one of four treatment groups: LIVALO (2 mg or 4 mg) or atorvastatin (10 mg or 20 mg), once daily. Results showed that LIVALO was comparable to atorvastatin in terms of reduction in LDL-C, and no significant differences emerged in the other endpoints. Adverse events with LIVALO and atorvastatin were also similar.

Study 2

A total of 857 patients were randomized to LIVALO (2 mg or 4 mg) or simvastatin (20 mg or 40 mg), once daily. Results showed that LIVALO 4 mg and simvastatin 40 mg were comparable in LDLC reduction, with low-dose LIVALO (2 mg) resulting in a greater reduction in LDL-C than simvastatin 20 mg. Additionally, low-dose LIVALO also showed significantly better decreases in total cholesterol and non-HDL-C than simvastatin 20 mg. Moreover, the percentage of patients who met the LDL-C goal, according to EAS guidelines, was also greater with low-dose LIVALO compared with simvastatin 20 mg. The tolerability profiles of LIVALO and simvastatin were similar.

Extension Study

The extension study demonstrated a favorable safety and tolerability profile for LIVALO 4 mg over the 52-week trial. Reductions in LDL-C were sustained over the 52-week period. In addition, a higher proportion of LIVALO-treated patients met the defined LDL-C target at the end of the extension study than at the end of the core study (74.0% NCEP and 73.5% EAS). Steady increases in HDL-C were observed throughout the extension period, reaching more than 14%
'/>"/>

SOURCE Kowa Company Ltd., Kowa Pharmaceuticals America, Inc., and Kowa Research Institute, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
2. Noteworthy Medical Systems Demonstrates National Health Information Network (NHIN) Interoperability
3. Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation
4. Advanced Life Sciences Restanza Demonstrates Efficacy in Treating Anthrax Infection
5. Survey Demonstrates Marin County Residents Support Locally Owned and Operated Marin General Hospital
6. EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) Therapy
7. VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
8. CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges
9. Study demonstrates the anti-inflammatory properties of pine bark extract
10. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
11. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Inc. (MTA) has selected IFN as a fiber transport ... Sales Manager, fiber route diversity and network redundancy are ... MTA with the diverse fiber transport from their Merrillville ... voice carriers located at Henry Street in Indianapolis, IN. ...
(Date:5/24/2015)... Lake Geneva, WI (PRWEB) May 24, ... Bea Mercy Health System CEO ... their principal and honored at the ... event held April 15 at Geneva ... include (by school): ,     -Badger High ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 ... Branches Florida City exactly five years to the day after ... , A large fire tore through the Branches United Methodist ... in the middle of the night as neighbors, staff and ... arson even though it is suspected that the fire began ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2
... National Scoliosis Awareness Month in June 2008, ... Golden, who survived scoliosis surgery to become a,nationally-ranked ... spokespersons for,the National Scoliosis Foundation. The other spokesperson, ... to competitive dancing after recovering,from her scoliosis surgery ...
... Steven Small, professor of neurology and psychology at the ... Milton, are among a group science writers and neuroscientists ... of Players and Fans, a new book that explores ... as athletes, coaches and fans. , Using baseball ...
... March 11 NHS Choices ( http://www.nhs.uk ), the,digital ... calculator that will,allow users to see both the physical ... Based on NHS accredited information, the interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ... of quitting - totting up how much you could ...
... March 11 Benchmarked companies,ranked skills application/productivity ... before and after testing ranked as a ... according to research by Best,Practices, LLC, a ... complimentary sample of this research, "Optimizing Sales,Training ...
... ... CEOs say, TALLAHASSEE, Fla., March ... to,eliminate the state,s planning process for new hospitals, warning it would,further destabilize ... the elderly and poor, and already grappling with,serious shortages of doctors and ...
... market for wireless,and mobile phone based healthcare platforms ... drive down costs. According to a report published,this ... communications platforms provide a relatively simple means of,connecting ... and advanced Health 2.0 based services being developed ...
Cached Medicine News:Health News:Author Elizabeth Golden and Dancer Sarah Patellos to Serve as National Spokespersons for the National Scoliosis Foundation 2Health News:Author Elizabeth Golden and Dancer Sarah Patellos to Serve as National Spokespersons for the National Scoliosis Foundation 3Health News:Chicago neuroscientist contributes to book on brains and baseball 2Health News:Skills Application and Productivity Rank as the Most Effective Training Measures for First-Year Pharmaceutical Reps 2Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 2Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 3Health News:Wireless Platforms Key to Joined-up Healthcare 2
(Date:5/22/2015)... Calif. , May 22, 2015 /PRNewswire/ ... the Company has commenced termination of its ... brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... inhibitor, is in development for patients with ... spondyloarthritis.  The decision was based on events ...
(Date:5/22/2015)... ORLANDO, Fla. , May 22, 2015 ... Copay Assistance Program. This program provides financial assistance for ... "We are pleased to announce the addition of the ... programs," stated Mark McGreevy , executive director. "With ... mission and vision of a world where no one ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... Aeras and the China National Biotech Group (CNBG) today announced ... to pursue opportunities to jointly develop tuberculosis (TB) vaccines in ... The partnership is intended to leverage both organizations, capabilities ... major public health priority in China, where there are more ...
... 25, 2011 Ultra Clean Holdings, Inc. (Nasdaq: ... for the semiconductor capital equipment, flat panel, medical, energy and ... quarter of fiscal year 2011 ended July 1, 2011.   ... an increase of 5.5% from the first quarter 2011 and ...
Cached Medicine Technology:Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration 2Ultra Clean Reports Second Quarter 2011 Financial Results 2Ultra Clean Reports Second Quarter 2011 Financial Results 3Ultra Clean Reports Second Quarter 2011 Financial Results 4
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
... The CoaguChek XS system is a compact, ... patients to experience a significant improvement in ... management of their condition. , , The ... to the proven CoaguChek S system. It ...
Medicine Products: